Learn more about our research and the published findings of the Starczynowski Lab.
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Journal of Hematology and Oncology. 2022; 15:70..
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discovery. 2022; 12:2392-2413..
IKAROS and MENIN in synergy in AML. 2022; 3:528-529..
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 2022; 14:eabb7695..
Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Advances. 2022; 6:1186-1192..
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022; 29:298-314.e9..
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022; 36:438-451..
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 2022; 29:8-19..
Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Cancer Discovery. 2022; 12:250-269..
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021; 28:1966-1981.e6..
TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling. Cell Reports. 2021; 36:109386..
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. The Journal of Experimental Medicine. 2021; 218:e20201544..
Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell. 2021; 28:1074-1089.e7..
2021; 10:1-60.. Systemic inflammation recruits fast-acting anti-inflammatory innate myeloid progenitors from BM into lymphatics. eLife.
Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics. eLife. 2021; 10:e66190..
TNFAIP3 Plays a Role in Aging of the Hematopoietic System. Frontiers in Immunology. 2020; 11:536442..
FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer Journal. 2020; 10:98..
HHEX expression drives AML development. Blood. 2020; 136:1575-1576..
TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Experimental Hematology. 2020; 90:18-29..
Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology. 2020; 21:535-545..
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. The Journal of Clinical Investigation. 2020; 130:2017-2023..
TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. Cell Reports. 2020; 30:2776-2790.e6..
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia and Lymphoma. 2019; 60:3161-3171..
2019; 134:3934.. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood.
2019; 134:4224.. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML. Blood.
2019; 134:2983.. Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia. Blood.
2019; 134:4271.. Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. Blood.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 2019; 11:eaaw8828..
Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease. Current Opinion in Cell Biology. 2019; 58:85-94..
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology. 2019; 21:640-650..
Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018; 132:1553-1560..
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances. 2018; 2:2491-2504..